Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics
company, today announced that nine abstracts focused on its
Decipher Prostate and Decipher Bladder Genomic Classifiers will be
presented at AUA 2024, the annual meeting of the American
Urological Association, taking place May 3-6 in San Antonio.
Studies to be presented include those that evaluate the clinical
utility of the company’s Decipher tests in guiding treatment
decisions for patients with prostate or bladder cancer. Other
presentations will explore new insights into these cancers’
underlying biology, which researchers derived through use of
Veracyte’s whole-transcriptome-based Decipher GRID research
tool.
“The data being presented at AUA 2024 expands the extensive
clinical evidence supporting our Decipher Prostate and Decipher
Bladder tests,” said Elai Davicioni, Ph.D., Veracyte’s medical
director for Urology. “They also highlight Veracyte’s commitment to
collaborating with leading researchers to help understand the
biological underpinnings of urologic cancers and advance the
science around the disease areas we serve.”
The following abstracts will be presented in the Henry B.
González Convention Center:
Title:
High Decipher score defines the subgroup
most at risk of metastatic progression among patients with lower
grade tumors classified as NCCN high-risk based on elevated
prostate-specific antigen level alone
Presenter:
David Han, M.D., Columbia University
Irving Medical Center
Format:
Poster (MP41-14)
Date/Time:
Saturday, May 4, 2024 / 3:30 p.m. to 5:30
p.m. CT
Room #:
304B
Title:
Decipher® Predicts Clinically Significant
Upgrading on Final Radical Prostatectomy Pathology
Presenter:
John Sheng, M.D., Rutgers New Jersey
Medical School
Format:
Poster (MP49-09)
Date/Time:
Sunday, May 5, 2024 / 7:00 a.m. to 9:00
a.m. CT
Room #:
221B
Title:
Genomic Signatures Associated with Adverse
Pathologic Features at Radical Prostatectomy Among Active
Surveillance Eligible Men
Presenter:
Eric Li, M.D., Northwestern University
Format:
Poster (MP41-09)
Date/Time:
Saturday, May 4, 2024 / 3:30 p.m. to 5:30
p.m. CT
Room #:
304B
Title:
Variation in Prostate Cancer Genomic
Subtypes Across Prostate Magnetic Resonance Imaging PIRADS Scores
and Race
Presenter:
Nimrod Barashi Gozal, M.D., Washington
University in St. Louis
Format:
Podium Presentation (PD42-01)
Date/Time:
Sunday, May 5, 2024 / 9:30 a.m. to 9:40
a.m. CT
Room #:
303A
Title:
Transcriptomic Features of Clinically
Localized Prostate Cancer Arising from Distinct Prostate Zonal
Regions
Presenter:
Ross Liao, M.D., Cleveland Clinic
Format:
Poster (MP41-13)
Date/Time:
Saturday, May 4, 2024 / 3:30 p.m. to 5:30
p.m. CT
Room #:
304B
Title:
Glucagon-like peptide-1 Expression in
Prostate Cancer
Presenter:
Mohammed Shahait, M.D., Private
Practice
Format:
Poster (MP05-10)
Date/Time:
Friday, May 3, 2024 / 7:00 a.m. to 9:00
a.m. CT
Room #:
221C
Title:
Molecular subtyping for predicting
non-organ confined disease and survival outcomes after radical
cystectomy in clinical high-grade T1 and T2 bladder cancer
patients
Presenter:
Yair Lotan, M.D., UT Southwestern Medical
Center
Format:
Poster (MP15-07)
Date/Time:
Friday, May 3, 2024 / 1:00 p.m. to 3:00
p.m. CT
Room #:
221C
Title:
The stroma-rich consensus bladder cancer
subtype correlates with improved prognosis after neoadjuvant
immunotherapy and radical cystectomy
Presenter:
Joep De Jong, Ph.D., Erasmus MC, The
Netherlands
Format:
Podium Presentation (PD14-05)
Date/Time:
Friday, May 3, 2024 / 4:10 p.m. to 4:20
p.m. CT
Room #:
301A
Title:
A lncRNA-based classifier identifies high
grade T1 bladder cancer patients with excellent outcomes after
radical cystectomy
Presenter:
Yair Lotan, M.D., UT Southwestern Medical
Center
Format:
Poster (MP15-02)
Date/Time:
Friday, May 3, 2024 / 1:00 p.m. to 3:00
p.m. CT
Room #:
221C
Additional information regarding these presentations and
Veracyte’s participation at AUA 2024 can be found at the company’s
booth (#607).
About Decipher Prostate
The Decipher Prostate Genomic Classifier is a 22-gene test,
developed using RNA whole-transcriptome analysis and machine
learning, that helps inform treatment decisions for patients with
prostate cancer. The test is performed on biopsy or surgically
resected samples and provides an accurate risk of developing
metastasis with standard treatment. Armed with this information,
the physician can better personalize their patients’ care and may
recommend less-intensive options for those at lower risk or
earlier, more-intensive treatment for those at higher risk of
metastasis. The Decipher Prostate test has been validated in more
than 75 studies involving more than 100,000 patients. More
information about the Decipher Prostate test can be found here.
About Decipher Bladder
The Decipher Bladder Genomic Classifier is a 219-gene test,
developed using RNA whole-transcriptome analysis and machine
learning, that is designed for use in patients following bladder
cancer diagnosis who face questions regarding treatment intensity.
The test classifies bladder tumors into five molecular subtypes,
each having distinct tumor biology and potential clinical
implications. This information can help physicians and their
patients better understand the degree of benefit that would likely
be gained from neoadjuvant chemotherapy and/or the likelihood of
harboring non-organ-confined disease at time of surgery,
respectively. More information about the Decipher Bladder test can
be found here.
About Decipher GRID
The Decipher GRID database includes more than 200,000
whole-transcriptome profiles from patients with urologic cancers
and is used by Veracyte and its partners to contribute to continued
research and help advance understanding of prostate and other
urologic cancers. GRID-derived information is available on a
Research Use Only basis. More Information about Decipher GRID can
be found here.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose
vision is to transform cancer care for patients all over the world.
We empower clinicians with the high-value insights they need to
guide and assure patients at pivotal moments in the race to
diagnose and treat cancer. Our Veracyte Diagnostics Platform
delivers high-performing cancer tests that are fueled by broad
genomic and clinical data, deep bioinformatic and AI capabilities,
and a powerful evidence-generation engine, which ultimately drives
durable reimbursement and guideline inclusion for our tests, along
with new insights to support continued innovation and pipeline
development. For more information, please visit www.veracyte.com
and follow the company on X (formerly Twitter) at @veracyte.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to our statements related to the
potential impact these studies may have on advancing the science
around Decipher in prostate and bladder cancer. Forward-looking
statements can be identified by words such as: “appears,”
“anticipate,” “intend,” “plan,” “expect,” “believe,” “should,”
“may,” “will,” “enable,” “positioned,” “offers,” “designed” and
similar references to future periods. Actual results may differ
materially from those projected or suggested in any forward-looking
statements. These statements involve risks and uncertainties, which
could cause actual results to differ materially from our
predictions, and include, but are not limited to the potential
impact Decipher GRID can have on scientific advancements in
prostate cancer and, in turn, patients. Additional factors that may
impact these forward-looking statements can be found under the
caption “Risk Factors” in our Annual Report on Form 10-K filed on
March 1, 2024. Copies of these documents, when available, may be
found in the Investors section of our website at
https://investor.veracyte.com. These forward-looking statements
speak only as of the date hereof and, except as required by law, we
specifically disclaim any obligation to update these
forward-looking statements or reasons why actual results might
differ, whether as a result of new information, future events or
otherwise. These forward-looking statements speak only as of the
date hereof and, except as required by law, we specifically
disclaim any obligation to update these forward-looking statements
or reasons why actual results might differ, whether as a result of
new information, future events or otherwise.
Veracyte, the Veracyte logo, and Decipher are registered
trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and
selected countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240416752482/en/
Investors: Shayla Gorman investors@veracyte.com
619-393-1545
Media: Tracy Morris media@veracyte.com 650-380-4413
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024